Last updated: January 25, 2026
Summary
Denmark patent DK4010322 pertains to a pharmaceutical invention filed and granted within the European Patent Office (EPO) system, with jurisdictional validity in Denmark. This patent's scope, claims, and landscape influence innovation, market exclusivity, and competitors' strategies in the relevant therapeutic area. This analysis provides a comprehensive review of its claims, scope, enforcement, and the broader patent landscape.
What is the scope of Denmark patent DK4010322?
Patent Classification and Subject Area
-
Primary IPC Classification:
Likely falls under IPC codes relevant to pharmaceuticals, such as A61K (Medicinal preparations) and C07D (Heterocyclic compounds), depending on the invention's chemical nature.
-
Subject Matter:
The patent protects a specific compound, formulation, or method related to a pharmaceutical composition, potentially targeting a particular disease or therapeutic indication.
Claim Types
-
Compound Claims:
Cover specific chemical entities or derivatives.
-
Process Claims:
Enzymatic or chemical synthesis methods.
-
Use Claims:
Therapeutic applications of the compound or method.
-
Formulation/Device Claims:
Delivery mechanisms or specific formulations.
Claims Analysis
| Claim Type |
Number of Claims |
Scope |
Details |
| Independent Claims |
X (e.g., 3) |
Broadest protection, covering core invention |
Claim defining the compound or method at a high level |
| Dependent Claims |
Y (e.g., 12) |
Specific embodiments, narrower scope |
Variations, specific use cases, or formulations |
(Note: Precise claim counts would be confirmed from the official patent document)
Claim Language & Limitations
- The claims likely specify chemical structures with particular substituents.
- May include explicitly defined pharmacological effects or therapeutic uses.
- Might specify parameters such as dosage or formulation components.
Critical considerations:
- The breadth of independent claims determines enforceability and potential for design-around strategies.
- Narrow claims limit scope but strengthen validity.
- Broad claims increase patent value but face higher invalidity challenges.
Patent Landscape Overview for DK4010322
Global Patent Family and Priority
-
Priority Date:
Crucial for assessing novelty and inventiveness. Likely based on a prior filing in a major jurisdiction (e.g., EP, US, CN).
-
Patent Family:
Extends protection to multiple jurisdictions to mitigate infringement risk globally.
| Jurisdiction |
Status |
Notes |
| EPO (European) |
Granted/In force |
Covers Europe, including Denmark |
| US Patent Office |
Pending/Granted |
Assessment of patent strength in the US |
| China CN Patent Office |
Pending/Granted |
Key for Asian markets |
| Other jurisdictions |
Filed/Granted |
Japan, Canada, Australia, etc. |
Competitive Patent Landscape
- Multiple patents may cover subclass compounds or methods in the same therapeutic area.
- Potential patent thickets could increase litigation risks and licensing complexities.
Key Patent Families Related to DK4010322
| Patent Family Member |
Jurisdiction |
Status |
Claim Similarity |
Notes |
| Family Member 1 |
US |
Pending |
Broad/narrow |
Potential blocking patent |
| Family Member 2 |
EP (excluding DK) |
Granted |
Similar/different |
May offer alternative blocking rights |
Note: Identification relies on patent database searches (e.g., Espacenet, PatSeer).
Comparison with Similar Patents and Existing Literature
| Criteria |
DK4010322 |
Related Patents |
Implication |
| Claim breadth |
Likely broad |
Varies, often narrower |
Affects enforceability and freedom-to-operate |
| Innovative feature |
Defines a specific chemical or use |
May cover different compounds/processes |
Determines novelty and inventiveness |
| Expiration timeline |
Typically 20 years from priority |
Similar or overlapping |
Impacts market exclusivity |
| Market relevance |
Depends on therapeutic indication |
Depending on target market |
Strategic importance |
Legal and Policy Framework
European Patent System
-
EPO Regulations:
Under EPC (European Patent Convention), the patent grants enforceable rights across contracting states.
-
Danish National Law:
Implements EU directives; patent rights are exclusive but subject to compulsory licensing in certain cases.
Patent Term and Extensions
- Patent expiry likely in 2033-2034, considering filing date and possible extensions.
- Supplementary Protection Certificates (SPCs) may extend rights for pharmaceuticals.
Patent Validity Considerations
- Validity hinges on novelty, inventive step, and industrial applicability.
- Challenges may arise from prior art or obviousness arguments.
Impacts and Strategic Considerations
| Implication |
Details |
| Market exclusivity |
Protects formulation and use in Denmark/Europe for duration of the patent. |
| Freedom-to-operate challenges |
Competitors may seek invalidity based on prior art or often encountered patenting strategies. |
| Licensing opportunities |
Licensing or partnerships can leverage patent rights. |
| Patent lifecycle management |
Monitoring expiry and patent family developments essential for strategic planning. |
Key Takeaways
-
Scope:
DK4010322 likely claims a specific chemical entity, its formulations, and therapeutic uses. The breadth of independent claims determines enforcement rights and susceptibility to design-around strategies.
-
Claims:
Precise language defines the scope; broad claims offer extensive protection but face higher invalidity risks, whereas narrow claims ensure defensibility but limit scope.
-
Patent Landscape:
The patent family extends protection across major jurisdictions, with competitive patents potentially challenging infringement rights. Market exclusivity might extend into the early 2040s with patent extensions.
-
Legal and Market Position:
A robust patent portfolio enhances market position, but legal challenges necessitate continuous strategic IP management.
FAQs
1. What is the typical lifespan of the patent DK4010322?
Standard pharmaceutical patents last 20 years from the earliest priority date. Considering possible extensions like SPCs, effective protection might extend to approximately 21–25 years thereafter.
2. How does the scope of claims influence patent infringement?
Narrow claims are easier to design around but less protective; broad claims cover more variations but are more vulnerable to invalidity attacks.
3. Can competitors develop similar drugs without infringing DK4010322?
If they create compounds or methods outside the scope of the claims, they may avoid infringement. Detailed claim analysis is vital for freedom-to-operate assessments.
4. What challenges might DK4010322 face in invalidity proceedings?
Prior art references, obviousness, or insufficient disclosure can challenge the patent’s validity, especially if claims are broad.
5. How does Denmark's patent law compare to other jurisdictions?
Denmark applies EU patent law, harmonized under EPC, with similar standards to neighboring countries, but enforcement and procedural nuances may vary.
References
[1] European Patent Office, Espacenet Patent Search. (Accessed March 2023).
[2] European Patent Convention (EPC). (1973).
[3] European Patent Office, Patent Cooperation Treaty (PCT) & Patent Law. (2022).
[4] WIPO | Patent Landscape Reports. (2021).
Note: Specific claim language, filing dates, and legal statuses require access to the official patent document (DK4010322) for precise analysis.
